

April 1st, 2023-

## Notice Concerning the Adoption of "Drug Discovery Support Promotion Project - Pre-designation Commercialization Support Project for Orphan Drugs"

We announce that our "Development of Breakthrough Therapy for Central Retinal Artery Occlusion (CRAO) (KUS121 Injection)" has been selected by the Japan Agency for Medical Research and Development (AMED) in its FY2023 "Drug Discovery Support Promotion Program - Pre-designation Commercialization Support Program for Orphan Drugs -".

The purpose of AMED's "Drug Discovery Support Promotion Project - Pre-designation Commercialization Support Project for Orphan Drugs" is to promote the development of orphan drugs by R&D-oriented companies aiming to obtain manufacturing and marketing approval, and to create an environment that will enable the rapid and effective commercialization of orphan drugs. AMED will provide support of up to 100 million yen per year for a period of three years.

With the support of AMED, we will start Phase II study of CRAO in the U.S. and proceed with the development quickly and proactively.

CRAO is still one of the diseases without a curative drug. We are committed to developing KUS121 so that it can be a gospel for patients with intractable eye diseases around the world. Sakae Muto, CEO